ArticleCancer medicine2015
Vismodegib, an antagonist of hedgehog signaling, directly alters taste molecular signaling in taste buds.
Article in Cancer medicine, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
45 citing papers in PubMed, 65 citations in OpenAlex.
- Tyrosine kinase inhibitors affect sweet taste and dysregulate fate selection of specific taste bud cell subtypes via KIT inhibition.Development (Cambridge, England) · 2026Article
- Single-Cell Transcriptomic Analysis of Salivary Epithelial Cells Reveals Large-Scale Dysregulation in Bitter Taste Dysfunction.International journal of molecular sciences · 2026Article
- Taste alterations in patients with cancer: an overview and recommendations for future research.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2025Review
- c-Kit signaling confers damage-resistance to sweet taste cells upon nerve injury.International journal of oral science · 2025Article
- Real-world safety of Tepotinib: Insights from the Food and Drug Administration Adverse Event Reporting System.PloS one · 2025Article
- Developing and regenerating a sense of taste.Current topics in developmental biology · 2025Review
- Cutaneous Side Effects of Modern Targeted Therapy and Immunotherapy in Patients with Dermatological Malignancies.Cancers · 2023Review
- Physiology of the tongue with emphasis on taste transduction.Physiological reviews · 2023Review
- Single-cell transcriptomics uncovers the differentiation of a subset of murine esophageal progenitors into taste buds in vivo.Science advances · 2023Article
- Anterior and Posterior Tongue Regions and Taste Papillae: Distinct Roles and Regulatory Mechanisms with an Emphasis on Hedgehog Signaling and Antagonism.International journal of molecular sciences · 2023Review
- Cisplatin attenuates taste cell homeostasis and induces inflammatory activation in the circumvallate papilla.Theranostics · 2023Article
- Brain-derived neurotrophic factor overexpression in taste buds diminishes chemotherapy induced taste loss.The European journal of neuroscience · 2022Article
- To Detect and Reject, Parallel Roles for Taste and Immunity.Current nutrition reports · 2021Review
- Glucagon-Like Peptide 1 and Taste Perception: From Molecular Mechanisms to Potential Clinical Implications.International journal of molecular sciences · 2021Review
- Taste and Smell Function in Head and Neck Cancer Survivors.Chemical senses · 2021Article
- Reciprocal signals between nerve and epithelium: how do neurons talk with epithelial cells?American journal of stem cells · 2021Review
- A Mechanistic Overview of Taste Bud Maintenance and Impairment in Cancer Therapies.Chemical senses · 2021Review
- Drinking Ice-Cold Water Reduces the Severity of Anticancer Drug-Induced Taste Dysfunction in Mice.International journal of molecular sciences · 2020Article
- Astrocytic Sonic Hedgehog Alleviates Intracerebral Hemorrhagic Brain InjuryFrontiers in cellular neuroscience · 2020Article
- Chemosensory Changes from Cancer Treatment and Their Effects on Patients' Food Behavior: A Scoping Review.Nutrients · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
Abstract
Vismodegib, a highly selective inhibitor of hedgehog (Hh) pathway, is an approved treatment for basal-cell carcinoma. Patients on treatment with vismodegib often report profound alterations in taste sensation. The cellular mechanisms underlying the alterations have not been studied. Sonic Hh (Shh) signaling is required for cell growth and differentiation. In taste buds, Shh is exclusively expressed in type IV taste cells, which are undifferentiated basal cells and the precursors of the three types of taste sensing cells. Thus, we investigated if vismodegib has an inhibitory effect on taste cell turnover because of its known effects on Hh signaling. We gavaged C57BL/6J male mice daily with either vehicle or 30 mg/kg vismodegib for 15 weeks. The gustatory behavior and immunohistochemical profile of taste cells were examined. Vismodegib-treated mice showed decreased growth rate and behavioral responsivity to sweet and bitter stimuli, compared to vehicle-treated mice. We found that vismodegib-treated mice had significant reductions in taste bud size and numbers of taste cells per taste bud. Additionally, vismodegib treatment resulted in decreased numbers of Ki67- and Shh-expressing cells in taste buds. The numbers of phospholipase Cβ2- and α-gustducin-expressing cells, which contain biochemical machinery for sweet and bitter sensing, were reduced in vismodegib-treated mice. Furthermore, vismodegib treatment resulted in reduction in numbers of T1R3, glucagon-like peptide-1, and glucagon-expressing cells, which are known to modulate sweet taste sensitivity. These results suggest that inhibition of Shh signaling by vismodegib treatment directly results in alteration of taste due to local effects in taste buds.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.